Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?

Publisher： Karger

E-ISSN： 2296-5262|23|3|2-6

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.3, 2000-05, pp. : 2-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 177-182

Karger

Access to resources Recommend Favorite

Assessing the quality of life in phase I and II anti-cancer drug trials: interviews versus questionnaires

By Cox K.  

Social Science and Medicine, Vol. 58, Iss. 3, 2004-02 ,pp. : 661-661

Elsevier

Access to resources Recommend Favorite

1. Phase I and Phase II Study Groups

By  

Oncology Research and Treatment, Vol. 21, Iss. 3, 1998-07 ,pp. : 1-61

Karger

Access to resources Recommend Favorite

Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL‐5010)

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 1, 2015-07 ,pp. : 247-249

John Wiley & Sons Inc

Access to resources Recommend Favorite

AQW051, a novel α7‐nACh receptor partial agonist

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 5, 2015-03 ,pp. : 1292-1304

John Wiley & Sons Inc

Access to resources Recommend Favorite